Caribou Biosciences (CRBU) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Caribou Biosciences

NasdaqGS•Healthcare•Biotechnology

$1.570.00(0.00%)Market closed

Market Cap

$132.29M

P/S

13.2x

P/B

1.3x

Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

How this company scores

AverageMetricSide Score: 48/100

Strongest: Growth (17/25); weakest: Cash & Earnings Quality (8/25).

Profitability8/25

Growth17/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality8/25

Strengths

Interest easily coveredProfit converts from growthNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 13.2x5y range 4.5x – 45.7x

Currently near its 18-quarter median.

P/B · 1.3x5y range 0.4x – 2.7x

Currently near its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $132.29M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $10.04M
Q. Revenue: $1.50M
TTM EBITDA: $-105.09M
TTM Op. Income: $-109.47M
Q. Op. Income: $-25.34M
TTM Net Income: $-103.40M
Q. Net Income: $-24.28M
EPS: $-0.24
Shares Out.: $100.99M

$10.04M in TTM revenue grew 10.0% YoY, reaching $1.50M last quarter. TTM EBITDA of $-105.09M and TTM operating income of $-109.47M show growth is flowing through to the bottom line. However, net income is negative at $103.40M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is up 10% — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -1648.7%
Op. Margin: -1690.4%
Net Margin: -1619.9%

Op. margin of -1690.4% is up 93.6% YoY — cost efficiency is improving. Net margin at -1619.9% Across the last 8 quarters, operating margin has fallen for 2 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 13.2x
P/B Ratio: 1.3x

P/S of 13.2x and P/B of 1.3x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $142.77M
Cash: $26.19M
Long-Term Debt: N/A
Book Value: $98.10M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-22.79M
TTM Free Cash Flow: $-95.75M
FCF Margin: -954.2%
FCF / Net Income: 0.9

TTM FCF of $-95.75M on $-22.79M in operating cash flow. The FCF / Net Income ratio of 0.9x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 6 consecutive quarters — an improving trend.